Ipamorelin (original) (raw)

Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from . Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by for the treatment of postoperative ileus, but was discontinued due to lack of efficacy. Ipamorelin has been used by athletes as a performance enhancing drug.